Osborne Clarke. (2/25/21). "Press Release: Osborne Clarke Advised Delphi Genetics on Its Acquisition by Catalent".

	Organisation	Osborne Clarke (Brussels)
	Group	Osborne Clarke (Group)
	Organisation 2	Delphi Genetics S.A.
	Group	Catalent (Group)
	Product	legal services
	Product 2	plasmid DNA (pDNA)
	Index term	Delphi Genetics–Osborne Clarke: legal services, 202102 supply service Osborne Clarke Brussels legal adviser to Delphi Genetics on sale Catalent
	Index term 2	Delphi Genetics–Catalent: investment, 202102– acquisition 100% valuing Delphi Genetics at $55m
	Person	Chef, Hadrien (Osborne Clarke 202102 Partner in Belgium)

International legal practice Osborne Clarke has advised Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, on its acquisition, by Catalent through an auction process in coordination with the US-based investment bank, Achelous Partners. The sale was completed with a valuation of the company at 55 million USD.

The team was led by Partner Hadrien Chef and included Laurent De Pauw (Associate, Corporate), Tonya Aelbrecht (Senior Associate, Corporate), Karen Calvo Vleugels (Junior Associate, Corporate), Benjamin Docquir (Partner, IT/IP), Chloé Ponsart (Associate, IT/IP), Vinciane Rysselinck (Senior Counsel, Employment) and Olivier Lambillon, (Counsel, Tax).

This transactions demonstrates the ongoing full spectrum legal support provided by Osborne Clarke to life science & healthcare companies operating in Belgium’s growing biotech, medtech and pharma sector. Osborne Clarke combines sector knowledge and a global reach to support clients at all stages of business growth and the team has the extensive knowledge to guide clients as they navigate the complexities of R&D processes, fundraising and acquisitions, data protection, workforce strategies, and regulatory compliance.

About Delphi Genetics

Founded in 2001 as a spin off from the Université libre de Bruxelles (ULB), Delphi Genetics is a lead-ing bioproduction CDMO with capabilities in handling the entire plasmid DNA development and CGMP manufacturing process. Its operations are headquartered at a 17,000-square-foot (1,600-square-meter) facility, adjacent to Catalent’s current cell therapy facilities. Delphi has built a reputation for its ‘one-stop-shop’ capabilities that include process development, pilot production, plasmid design and production, strain screening and stability, and which span from preclinical to Phase 3 applications, using fully single-use technology.

About Catalent

Catalent is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Catalent’s acquisition of Delphi’s pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. With these new services, Catalent’s fully integrated cell and gene offering will allow customers to de-risk and optimize their programs along the entire development pipeline.

Connect with one of our experts

Hadrien Chef
Partner, Belgium
T +32 2 515 93 24
Email Hadrien [ hadrien.chef@osborneclarke.com ]
Full Biog

Laurent De Pauw
Associate, Belgium
M +32 498 74 48 06
Email Laurent
Full Biog

Tonya Aelbrecht
Senior Associate, Belgium
T +32 2 515 9344
Email Tonya
Full Biog

Karen Calvo Vleugels
Junior Associate, Belgium
T +32 2 515 9326
Email Karen
Full Biog

Benjamin Docquir
Partner, Belgium
T +32 2 515 93 36
Email Benjamin
Full Biog

Chloé Ponsart
Associate, Belgium
Email Chloé
Full Biog

Vinciane Rysselinck
Senior Counsel, Belgium
T +32 2 515 9308
Email Vinciane
Full Biog

Olivier Lambillon
Counsel, Belgium
T +32 2 515 93 34
Email Olivier
Full Biog

Record changed: 2022-02-05